Primary cutaneous follicle centre lymphoma medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overvew== | ==Overvew== | ||
The predominant therapy for primary cutaneous follicle centre lymphoma is [[radiotherapy]]. Adjunctive chemotherapy may be required. | |||
==Medical Therapy== | ==Medical Therapy== | ||
* Surgical removal and/or [[radiotherapy]] is given for localized disease.<ref name="Jaffe_2011_1"/>{{rp|314}}<ref name="Wilcox2015"/> | |||
* Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.<ref name="Jaffe_2011_1"/>{{rp|314}}<ref name="Armitage_2010_2"/><ref name="Sokol2012"/><ref name="Wilcox2015"/> | |||
* For the less common situation of more extensive disease (still confined to skin), [[rituximab]] without chemotherapy is used.<ref name="Jaffe_2011_1"/>{{rp|314}}<ref name="Armitage_2010_2"/><ref name="Sokol2012"/><ref name="Wilcox2015"/>Intralesional [[interferon alpha]] (IFN-α)<ref name="Senff2008"/> and intralesional rituximab have been used.<ref name="Jaffe_2011_1"/>{{rp|314}}<ref name="Senff2008"/> | |||
* Approximately one-third of PCFCL relapse, usually in the skin; treatment is similar to initial management<ref name="Wilcox2015"/> and overall survival remains excellent.<ref name="Suárez2013_2"/> | |||
{|style="margin: 0 auto;" | {|style="margin: 0 auto;" | ||
| [[File:Primary cutaneous follicle centre lympoma image 4.jpg|250px|thumb|upright|A 56-year old male patient with numerous erythematous and livid infiltrates before superficial radiotherapy.<ref name=biomedcentral>Radiotherapy of primary cutaneous follicle center lymphoma: case report and review of literature. BioMed Central. https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-8-147. Accessed on March 02, 2016</ref>]] | | [[File:Primary cutaneous follicle centre lympoma image 4.jpg|250px|thumb|upright|A 56-year old male patient with numerous erythematous and livid infiltrates before superficial radiotherapy.<ref name=biomedcentral>Radiotherapy of primary cutaneous follicle center lymphoma: case report and review of literature. BioMed Central. https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-8-147. Accessed on March 02, 2016</ref>]] | ||
Revision as of 13:57, 3 March 2016
|
Primary cutaneous follicle centre lymphoma Microchapters |
|
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary cutaneous follicle centre lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma medical therapy |
|
FDA on Primary cutaneous follicle centre lymphoma medical therapy |
|
CDC on Primary cutaneous follicle centre lymphoma medical therapy |
|
Primary cutaneous follicle centre lymphoma medical therapy in the news |
|
Blogs on Primary cutaneous follicle centre lymphoma medical therapy |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Primary cutaneous follicle centre lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overvew
The predominant therapy for primary cutaneous follicle centre lymphoma is radiotherapy. Adjunctive chemotherapy may be required.
Medical Therapy
- Surgical removal and/or radiotherapy is given for localized disease.[1]:314[2]
- Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.[1]:314[3][4][2]
- For the less common situation of more extensive disease (still confined to skin), rituximab without chemotherapy is used.[1]:314[3][4][2]Intralesional interferon alpha (IFN-α)[5] and intralesional rituximab have been used.[1]:314[5]
- Approximately one-third of PCFCL relapse, usually in the skin; treatment is similar to initial management[2] and overall survival remains excellent.[6]
 |
 |
 |
 |